MedTrace Logo

The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg

NCT06037473 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2600

Last updated 2025-09-04

No results posted yet for this study

Summary

In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.

Conditions

  • Growth Hormone Treatment
  • Growth Disorders

Interventions

DRUG

Polyethylene glycol recombinant human growth hormone injection

0.1-0.3mg/kg.w

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • Beijing Children's Hospital

    lead OTHER

Principal Investigators

  • Bingyan Cao, Dr. · Beijing Children's Hospital

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2029-01-01
Completion
2029-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06037473 on ClinicalTrials.gov